Aelis Farma SA (AELIS.PA)
EUR 1.24
(1.23%)
EUR 1.24
(1.23%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 12.35 Million EUR | 224.44% |
| 2022 | 3.8 Million EUR | -58.03% |
| 2021 | 9.07 Million EUR | 719.78% |
| 2020 | 1.1 Million EUR | 135.42% |
| 2019 | -3.12 Million EUR | -9.4% |
| 2018 | -2.85 Million EUR | -31.54% |
| 2017 | -2.17 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.06 Million EUR | 0.0% |
| 2024 Q1 | 2.06 Million EUR | 54.23% |
| 2023 Q2 | 2.85 Million EUR | 0.0% |
| 2023 FY | 12.35 Million EUR | 224.44% |
| 2023 Q3 | 3.32 Million EUR | 16.77% |
| 2023 Q1 | 2.85 Million EUR | 38.61% |
| 2023 Q4 | 1.33 Million EUR | -59.83% |
| 2022 Q2 | 2.12 Million EUR | 0.0% |
| 2022 Q4 | 2.05 Million EUR | 0.0% |
| 2022 FY | 3.8 Million EUR | -58.03% |
| 2022 Q1 | 2.12 Million EUR | 77.79% |
| 2022 Q3 | 2.05 Million EUR | -3.25% |
| 2021 Q2 | 4.18 Million EUR | 0.0% |
| 2021 Q1 | 4.18 Million EUR | 1085.69% |
| 2021 FY | 9.07 Million EUR | 719.78% |
| 2021 Q4 | 1.19 Million EUR | 0.0% |
| 2021 Q3 | 1.19 Million EUR | -71.44% |
| 2020 Q2 | 215.5 Thousand EUR | 0.0% |
| 2020 Q1 | 215.5 Thousand EUR | 0.0% |
| 2020 FY | 1.1 Million EUR | 135.42% |
| 2020 Q4 | 353 Thousand EUR | 0.0% |
| 2020 Q3 | 353 Thousand EUR | 63.81% |
| 2019 FY | -3.12 Million EUR | -9.4% |
| 2018 FY | -2.85 Million EUR | -31.54% |
| 2017 FY | -2.17 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -1899.676% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -215.738% |
| Adocia SA | 1.38 Million EUR | -792.274% |
| Biophytis S.A. | -803 Thousand EUR | 1638.979% |
| Advicenne S.A. | 1.42 Million EUR | -766.62% |
| genOway Société anonyme | 20.1 Million EUR | 38.519% |
| IntegraGen SA | 5.01 Million EUR | -146.26% |
| Medesis Pharma S.A. | -2.66 Million EUR | 563.755% |
| Neovacs S.A. | 29.31 Thousand EUR | -42057.331% |
| NFL Biosciences SA | -56.06 Thousand EUR | 22142.666% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -474.012% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 970.718% |
| Sensorion SA | 3.78 Million EUR | -226.253% |
| Theranexus Société Anonyme | -4.63 Million EUR | 366.411% |
| TME Pharma N.V. | -127 Thousand EUR | 9830.709% |
| Valbiotis SA | 2.66 Million EUR | -363.193% |
| TheraVet SA | -530.79 Thousand EUR | 2428.201% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -875.375% |
| DBV Technologies S.A. | 4.15 Million EUR | -197.096% |
| Genfit S.A. | 28.22 Million EUR | 56.215% |
| GeNeuro SA | -293.8 Thousand EUR | 4306.263% |
| Innate Pharma S.A. | -4.12 Million EUR | 399.879% |
| Inventiva S.A. | 17.5 Million EUR | 29.383% |
| MaaT Pharma SA | 1.65 Million EUR | -646.707% |
| MedinCell S.A. | 9.28 Million EUR | -33.053% |
| Nanobiotix S.A. | 36.2 Million EUR | 65.869% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -454.917% |
| Poxel S.A. | 1000.00 EUR | -1235700.0% |
| GenSight Biologics S.A. | 3 Million EUR | -311.933% |
| Transgene SA | -28.4 Million EUR | 143.508% |
| Valneva SE | 52.83 Million EUR | 76.611% |